Author: Qu, Hua; Zheng, Yi; Wang, Yuren; Li, Hongwei; Liu, Xiufei; Xiong, Xin; Zhang, Linlin; Gu, Jing; Yang, Gangyi; Zhu, Zhiming; Zheng, Hongting; Ouyang, Qin
Title: The potential effects of clinical antidiabetic agents on SARSâ€CoVâ€2 Cord-id: fqymqzv2 Document date: 2020_12_19
ID: fqymqzv2
Snippet: BACKGROUND: Coronavirus disease 2019 (COVIDâ€19), caused by severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2), is currently posing significant threats to public health worldwide. It is notable that a substantial proportion of patients with sever COVIDâ€19 have coexisting diabetic conditions, indicating the progression and outcome of COVIDâ€19 may relate to diabetes. However, it is still unclear whether diabetic treatment principles can be used for the treatment of COVIDâ€19.
Document: BACKGROUND: Coronavirus disease 2019 (COVIDâ€19), caused by severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2), is currently posing significant threats to public health worldwide. It is notable that a substantial proportion of patients with sever COVIDâ€19 have coexisting diabetic conditions, indicating the progression and outcome of COVIDâ€19 may relate to diabetes. However, it is still unclear whether diabetic treatment principles can be used for the treatment of COVIDâ€19. METHODS: We conducted a computational approach to screen all commonly used clinical oral hypoglycemic drugs to identify the potential inhibitors for the main protease (M(pro)) of SARSâ€CoVâ€2, which is one of the key drug targets for antiâ€COVIDâ€19 drug discovery. RESULTS: Six antidiabetic drugs with docking scores higher than 8.0 (cutoff value), including repaglinide, canagliflozin, glipizide, gliquidone, glimepiride, and linagliptin, were predicted as the promising inhibitors of M(pro). Interestingly, repaglinide, one of the six antidiabetic drugs with the highest docking score for M(pro), was similar to a previously predicted active molecule nelfinavir, which is a potential antiâ€HIV and antiâ€COVIDâ€19 drug. Moreover, we found repaglinide shared similar docking pose and pharmacophores with a reported ligand (N3 inhibitor) and nelfinavir, demonstrating that repaglinide would interact with M(pro) in a similar way. CONCLUSION: These results indicated that these six antidiabetic drugs may have an extra effect on the treatment of COVIDâ€19, although further studies are necessary to confirm these findings.
Search related documents:
Co phrase search for related documents- active molecule and acute respiratory syndrome: 1, 2, 3, 4
- active molecule and lopinavir ritonavir: 1
- acute respiratory disease and additional benefit: 1, 2
- acute respiratory disease and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory disease and lopinavir ritonavir therapy: 1, 2, 3
- acute respiratory disease and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9
- acute respiratory disease and lysis buffer: 1, 2, 3, 4
- acute respiratory syndrome and additional benefit: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- acute respiratory syndrome and lopinavir effect: 1, 2, 3, 4
- acute respiratory syndrome and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lopinavir ritonavir therapy: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
- acute respiratory syndrome and lopinavir ritonavir treatment: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute respiratory syndrome and lower rank: 1, 2
- acute respiratory syndrome and lysate protein: 1, 2, 3, 4
- acute respiratory syndrome and lysis buffer: 1, 2, 3
- additional benefit and lopinavir ritonavir: 1, 2
- additional benefit and lopinavir ritonavir treatment: 1
- lopinavir ritonavir and lower rank: 1
- lysate protein and lysis buffer: 1, 2, 3, 4
Co phrase search for related documents, hyperlinks ordered by date